Surrogate end points in heart failure trials

American Heart Journal

Volumn 145, Issue 2 SUPPL., 2003, Pages

  Gheorghiade, Mihai ^a   Adams Jr , Kirkwood F ^b   Gattis, Wendy A ^c   Teerlink, John R ^d   Orlandi, Cesare ^e   O'Connor, Christopher M ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FLOSEQUINAN; MILRINONE; MOXONIDINE; NEUROHORMONE; PIPERANOMETOZINE;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; EXERCISE TOLERANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HORMONE INHIBITION; HUMAN; MORTALITY; PRIORITY JOURNAL;

EID: 0037328765     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.159     Document Type: Conference Paper

References (22)

1. Temple RJ. A regulatory authority's opinion about surrogate end points. In: Nimmo WS, Tucker GT, editors. Clinical measurement in drug evaluation. New York: J Wiley; 1995.
2. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-52.
3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
4. Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
5. The Studies in Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. The Studies in Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
7. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-7.
8. The second Cardiac Insufficiency Bisoprolol Study (CIBIS-II) Investigators and Committee. CIBIS-II: a randomised trial. Lancet 1999;353:9-13.
9. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilal on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
10. Coats AJS. Heart failure 99 - the MOXCON story. Int J Cardiol 1999;71:109-11.
11. The Beta-Blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
12. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
13. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
14. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.
15. Califf RM, Adams KF, McKenna W, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
16. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin-converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET). Circulation 1993;88:492-501.
17. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal investigators of the Randomized Evaluation of Flosequinan on Exercise Tolerance (REFLECT) study. J Am Coll Cardiol 1993;22:65-72.
18. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study [abstract]. Circulation 1993;88(Suppl):1-301.
19. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with congestive heart failure: non-specific predictors of sudden death: results from the PROMISE study. Circulation 2000;101:40-6.
20. Echt DS, Liebson PR, Mitchell B, et al. Mortality and morbidity in patients receiving-encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1992;324:781-8.
21. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
22. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardial 2002;39:1414-21.